Pyridostigmine as Immunomodulator in People Living With HIV
Status:
Suspended
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Human immunodeficiency virus (HIV) infection is characterized by persistent immune activation
and a constant turnover of T cells. This leads to a precipitous fall in the number of T
cells, as well as to an early immunosenescence. This results in increased susceptibility to
opportunistic infections. In these patients, modulation of the immune response represents a
promising mechanism to maintain immunological homeostasis and prevent the development of
pathology. We hypothesize that the addition of pyridostigmine to the regular combined
antiretroviral therapy will result in a decrease in T cell overactivation and a reduction in
circulating inflammatory markers.
Phase:
Phase 2
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran